Achaogen received a $26.6 million contract spanning five years from the NIAID. The money will fund the discovery and development of compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis and Francisella tularensis.
The NIAID funding will support work to extend the spectrum and efficacy of its current leads and to advance one neoglycoside through Phase I trials.
Achaogen reports that its neoglycosides, or next-generation aminoglycosides, have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multidrug resistant Gram-negative organisms as well as multidrug resistant Gram-positive bacteria. These include Pseudomonas, Acinetobacter, Enterobacteriaceae, MRSA, and vancomycin-resistant Staphylococcus strains.